Technical Analysis for AVEO - AVEO Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 6.46 0.00% 0.00
AVEO closed unchanged on Wednesday, April 14, 2021, on 28 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical AVEO trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
200 DMA Support Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 200 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Older End-of-Day Signals for AVEO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 16 hours ago
Rose Above Previous Day's High about 22 hours ago
Up 2% about 22 hours ago
Up 1% about 22 hours ago
Down 2 % 2 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


AVEO Pharmaceuticals, Inc. Description

AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, operates as a cancer therapeutics company. The company engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its principal product candidate is tivozanib, for which the company has filed a new drug application with the U.S. food and drug administration as a proposed indication for the treatment of patients with advanced renal cell carcinoma (RCC). The company's product pipeline also comprises TAURUS, which is in a Phase II clinical study for the treatment of RCC. In addition, its product pipeline includes Biomarker Assessment of Tivozanib in ONcology program, such as BATON-RCC, a Phase II exploratory biomarker study in patients with advanced RCC; BATON-CRC, a Phase II clinical trial for the first-line therapy in patients with advanced metastatic colorectal cancer; and BATON-BC, a Phase II clinical trial for the treatment of patients with locally recurrent or metastatic triple negative breast cancer. Further, the company has a pipeline of monoclonal antibodies, including Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase II clinical stage for the treatment of non-small cell lung cancer; and AV-203, a monoclonal antibody that targets the ErbB3 receptor and is in Phase I clinical trial for the treatment of solid tumors. AVEO Pharmaceuticals, Inc. has strategic partnerships with Merck & Co., Inc; OSI Pharmaceuticals, Inc.; Kyowa Hakko Kirin; Astellas Pharma Inc.; and Biogen Idec, Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Drugs Antibodies Chemical Compounds Monoclonal Antibody Monoclonal Antibodies Cancer Treatments Breast Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Non Small Cell Lung Cancer Carcinoma Biomarker Colorectal Cancer Cancer Therapies Cancer Therapeutics Renal Cell Carcinoma Treatment Of Non Small Cell Lung Cancer Triple Negative Breast Cancer Metastatic Colorectal Cancer

Is AVEO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 18.24
52 Week Low 3.6
Average Volume 2,704,843
200-Day Moving Average 6.41
50-Day Moving Average 8.66
20-Day Moving Average 7.84
10-Day Moving Average 6.92
Average True Range 0.74
ADX 14.04
+DI 25.75
-DI 28.98
Chandelier Exit (Long, 3 ATRs ) 10.56
Chandelier Exit (Short, 3 ATRs ) 8.40
Upper Bollinger Band 10.73
Lower Bollinger Band 4.95
Percent B (%b) 0.26
BandWidth 73.82
MACD Line -0.74
MACD Signal Line -0.59
MACD Histogram -0.1472
Fundamentals Value
Market Cap 186.11 Million
Num Shares 28.8 Million
EPS 0.03
Price-to-Earnings (P/E) Ratio 230.71
Price-to-Sales 16.47
Price-to-Book 3.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.85
Resistance 3 (R3) 6.87 6.75 6.79
Resistance 2 (R2) 6.75 6.65 6.75 6.76
Resistance 1 (R1) 6.61 6.59 6.55 6.59 6.74
Pivot Point 6.49 6.49 6.47 6.49 6.49
Support 1 (S1) 6.35 6.39 6.29 6.33 6.18
Support 2 (S2) 6.23 6.33 6.23 6.16
Support 3 (S3) 6.09 6.23 6.14
Support 4 (S4) 6.07